Latest Articles

Publication Date
Novel insights into the role of Annexin A2 signaling pathway in female reproductive system diseases: from mechanisms to advanced therapies.

Annexin A2 (ANXA2) is a calcium-dependent protein with high affinity for phospholipids, and its multifunctional nature has drawn increasing attention in the onset and progression of various disorders of the …

Published: April 14, 2026, midnight
Novel Insights into the Pathogenic Role of CSF1R in Endometriosis.

Endometriosis (EM) is a prevalent gynecological disorder linked to pelvic pain, menstrual disturbances, and infertility. Despite its clinical burden, the molecular mechanisms underlying EM remain elusive, necessitating the discovery of …

Published: April 14, 2026, midnight
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer - TipRanks

BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer TipRanks

Published: April 13, 2026, 12:29 p.m.
PORTAL MADNESS: Scott Drew STEALS Elite Kentucky Target, He Wants to DESTROY Mark Pope? - newscentermaine.com

PORTAL MADNESS: Scott Drew STEALS Elite Kentucky Target, He Wants to DESTROY Mark Pope? newscentermaine.com

Published: April 13, 2026, 1:54 a.m.
Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.

Background/Objective: RNA modifications, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), N1-methyladenosine (m1A), pseudouridine (Ψ), N4-acetylcytidine (ac4C), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) and adenosine-to-inosine (A-to-I) editing, constitute a critical layer of post-transcriptional regulation that …

Published: April 13, 2026, midnight
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KELO-AM

GSK sees blockbuster potential in targeted cancer therapy after promising early data KELO-AM

Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KFGO

GSK sees blockbuster potential in targeted cancer therapy after promising early data KFGO

Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - WKZO

GSK sees blockbuster potential in targeted cancer therapy after promising early data WKZO

Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - WSAU

GSK sees blockbuster potential in targeted cancer therapy after promising early data WSAU

Published: April 12, 2026, 8:44 p.m.
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug - MedPage Today

Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug MedPage Today

Published: April 12, 2026, 8:01 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!